跳至主要内容
临床试验/NCT02334631
NCT02334631已完成4 期

A Double Blind Randomized Controlled Trial of High Volume Simethicone to Improve Visualization During Capsule Endoscopy

Lawson Health Research Institute1 个研究点 分布在 1 个国家目标入组 159 人开始时间: 2017年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
159
试验地点
1
主要终点
Visualization quality

研究概览

简要总结

Video capsule endoscopy (VCE) is a procedure where a small camera is swallowed to examine the small bowel. Although the procedure is useful for diagnosing small bowel diseases, air bubbles can obscure the recorded images. Simethicone is a medication that can be used to disperse the air bubbles. However, prior studies using this medication have shown only a modest benefit. In our study, we would like to investigate whether increasing the amount of medication will improve the recorded images further.

详细描述

BACKGROUND:

While VCE has become an important diagnostic tool for clinical practice, optimal preparation for VCE has yet to be determined.(13) The European Society of Gastrointestinal Endoscopy recommends bowel preparation but does not provide further details.(2) The Canadian Association of Gastroenterology, American Society of Gastrointestinal Endoscopy, American College of Gastroenterology, and American Gastroenterological Association make no specific recommendation. Many studies have addressed this knowledge gap, testing various regimens of purgatives.(14-18) A meta-analysis found that polyethylene glycol provided adequate visual quality in 68% of patients compared to 48% with fasting alone, while diagnostic yield climbed from 36% to 46%.(4) In contrast, oral preparation for colonoscopy produces adequate visualization in greater than 90% of patients.(19)

Intraluminal debris, bile, and air bubbles impair the visibility of small bowel mucosa during VCE. Simethicone, an anti-foaming agent, has been used with mixed success to improve image quality. Three studies investigated the addition of simethicone (30 mg, 600 mg, and 800 mg) to overnight fast, PEG, or mannitol demonstrated improvement in visualization with high preparation scores favouring the addition of simethicone.(7-9) In contrast, Wei and colleagues (10) compared simethicone (300 mg) + PEG with PEG alone and found that although simethicone improved visualization, adequate visualization was achieved in only 63% of patients. Similarly, Ge et al. (11) compared simethicone (300 mg) against fasting alone and found improvement in visualization with simethicone but this was limited to the proximal half of the small bowel and adequate visualization was limited to 55% of cases. Lastly, Rosa et al. (12) compared simethicone (100 mg) + PEG with PEG alone and did not find a difference in visualization score.

A potential reason for inconsistent improvement in small bowel visualization may be due to an inadequate volume of simethicone being delivered into the small bowel, especially the distal portions. Prior volumes of simethicone were small (<200 ml) and may have pooled in the stomach and become diluted by gastric juices before being delivered into the duodenum. Our hypothesis is that high volume simethicone may overcome this problem and improve small bowel cleansing to facilitate improved visualization during VCE.

STUDY DESIGN:

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
Triple (Participant, Care Provider, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

High volume simethicone

Experimental

High volume simethicone is defined as 1125 mg simethicone in 750 ml of water (1.5 mg/ml).

干预措施: High Volume Simethicone (Drug)

Standard volume simethicone

Active Comparator

Standard volume simethicone is defined as 300 mg simethicone in 200 ml of water (1.5 mg/ml).

干预措施: Standard Volume Simethicone (Drug)

结局指标

主要结局

Visualization quality

时间窗: Once during review of capsule images

Visualization quality will be scored in a blinded fashion using a validated score developed by Park et al. (World J Gastroenterol 2010;16(7):875-80.) Representative images from the small bowel will be serially selected at five-minute intervals. Each image is evaluated for two parameters: the proportion of visualized mucosa (VM) and degree of obscuration (DO) by bubbles, debris etc. The proportion of visualized mucosa is scored on a three- point scale: \> 75% = 3, 50% to 75% = 2, 25% to 50% = 1, \<25% = 0. The degree of obscuration is also scored in a three point scale: \< 5 % = 3, 5% to 25% = 2, 25% to 50% = 1, \> 50 % = 0. Mean scores for each parameter are obtained by dividing the sum of all images scored by the number of images. Finally the average of the two parameters is calculated. Both the whole, proximal, and distal small bowel will be scored separately. The first half of the small bowel will be considered proximal while the second half will be considered distal.

次要结局

  • Visualized mucosa sub-score(Once during review of capsule images)
  • Adverse Events(Once 7 days after the procedure.)
  • Small Bowel Transit Time(Once during review of capsule images)
  • Degree of obscuration sub-score(Once during review of capsule images)
  • Study Completion Rate(Once during review of capsule images)
  • Gastric Emptying Time(Once during review of capsule images)
  • Diagnostic Yield(Once during review of capsule images)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Michael Sai Lai Sey, MD

MD

Lawson Health Research Institute

研究点 (1)

Loading locations...

相似试验